Human genome editing and moral leadership: findings of the WHO Expert Advisory Committee
By Peter Mills,
Nuffield Council on Bioethics
| 07. 14. 2021
Assistant Director Pete Mills gives his reaction to the much-anticipated reports of the World Health Organization's Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing
In 2019, the World Health Organization convened an Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing. On Monday it published its findings in three reports: a position paper (summarising the findings), a set of recommendations and a framework for governance. These documents represent a significant contribution to the literature around genome editing that has emerged since about 2015, which includes a number of major reports and a steady stream of statements and position papers emanating from learned societies, professional bodies, national ethics committees and ad hoc groups. [1] The WHO report is both the latest of the ‘big reports’ and the last in the pipeline. For now.
The scope of the ‘big reports’ on human genome editing differs: the WHO covers laboratory research, medical uses and reproductive uses, or ‘somatic’, ‘germline’ and ‘heritable’ genome editing. The reports also have different emphases. The Nuffield Council has, naturally, been concerned with ethical, social and political matters. There was an implied division of labour between the International Commission (which reported in 2020) and the WHO Committee...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...